<DOC>
	<DOCNO>NCT01077622</DOCNO>
	<brief_summary>Ofatumumab IgG1κ fully human monoclonal antibody ( mAb ) specifically recognize epitope human differentiation antigen CD20 molecule . In vitro vivo study demonstrate ofatumumab depletes CD20 positive ( CD20+ ) B cell complement-dependent cytotoxicity ( CDC ) antibody-dependent cell-mediated cytotoxicity ( ADCC ) , result antitumour effect . This open-label study evaluate safety , tolerability , efficacy PK profile ofatumumab monotherapy chronic lymphocytic leukemia ( CLL ) patient . Ofatumumab administer intravenously first dose 300mg follow 7 weekly infusion 2000mg , follow 4 infusion 2000mg every 4 week . Primary objective study ( Part A ) evaluate tolerability , study ( Part B ) ass overall response rate CLL population . 10 subject enrol study . Subjects follow 48 week .</brief_summary>
	<brief_title>A Phase I/II , Single Arm , Open-label Study Ofatumumab ( GSK1841157 ) Patients With Previously Treated Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>Ofatumumab IgG1κ fully human monoclonal antibody ( mAb ) specifically recognize epitope human differentiation antigen CD20 molecule . In vitro vivo study demonstrate ofatumumab depletes CD20 positive ( CD20+ ) B cell complement-dependent cytotoxicity ( CDC ) antibody-dependent cell-mediated cytotoxicity ( ADCC ) , result antitumour effect . This open-label study evaluate safety , tolerability , efficacy PK profile ofatumumab monotherapy chronic lymphocytic leukemia ( CLL ) patient . Ofatumumab administer intravenously first dose 300mg follow 7 weekly infusion 2000mg , follow 4 infusion 2000mg every 4 week . Primary objective study ( Part A ) evaluate tolerability , study ( Part B ) ass overall response rate CLL population . 10 subject enrol study . Subjects follow 48 week .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subjects eligible enrolment study must meet follow criterion time screening : Patients give consent study participation sign informed consent form . Previously treat ( Patients receive least one prior CLL therapy either relapse refractory disease , require therapy . ) CLL least 5 x 109 B lymphocytes/ L ( 5000/μL ) . The diagnosis CLL require CD5 , CD19 , CD20 CD23 positivity , accord International Workshop Chronic Lymphocytic Leukemia ( IWCLL ) guideline [ Hallek , 2008 ] . Laboratory test value meet follow criterion indicate patient sufficient physiological function ; Neutrophils:1≥ 500 /mm3 ALT ≤ 2.5 time upper local normal limit Creatinine ≤ 1.5 time upper local normal limit Total bilirubin≤ 1.5 time upper local normal limit 1 : Patients receive hematopoietic cytokine GCSF preparation within 1 week screen laboratory test neutrophil counting . Patients pass follow period last anticancer treatment time screening : At least 4 week anticancer chemotherapy . At least 4 week anticancer radiotherapy . At least 4 week glucocorticoids treatment CLL unless ≤ 10 mg prednisolone /day . At least 12 week radioimmunotherapy and/or antibody therapy . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 , 1 , 2 . Life expectancy 24 week screen test . Aged ≥ 20 ( time signing informed consent ) . Patients possible stay trial site least two day ( day first infusion subsequent day ) . A subject eligible inclusion study follow criterion meet : Active malignancy need therapy anticancer drug , except CLL . Known Richter 's transformation . Previous autologous stem cell transplantation , within 24 week prior screen . Previous allogenic stem cell transplantation . Known CNS involvement . History significant cerebrovascular disease . Current cardiac disease require medical treatment ( e.g . atrial flutter treat acetylsalicylic acid beta block agent ) . Chronic active infectious disease require systemic ( intravenous oral ) treatment , limited , chronic renal infection , chronic chest infection bronchiectasis tuberculosis . Suspected/known immediate delay hypersensitivity component ofatumumab . Patients previously treat ofatumumab . Positive serology test HBsAg , antiHBcAb antiHCVAb . If antiHBcAb result positive , HBVDNA test performed . If HBVDNA result negative , patient eligible . HIV positivity . Pregnant lactating woman . Women childbearing potential willing use adequate contraception study one year last dose ofatumumab , male patient willing use adequate contraception study . Adequate contraception define follow limit ; Abstinence . Oral Contraceptive ( exclude oral progesterone alone ) . Intrauterine device ( IUD ) intrauterine system ( IUS ) . Male partner sterilization . Double barrier method : condom occlusive cap ( diaphragm cervical / vault cap ) plus spermicidal agent ( gel / film ) etc . Use investigational drug within 4 week prior screen . Current participation clinical study . Significant concurrent , uncontrolled medical condition include , limited , renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , neurological , cerebral psychiatric disease . Patients investigator ( sub investigator ) judge ineligible study . Note ; Childbearing potential : woman function ovary uterine , documented sterility ( i.e. , woman function ovary current document tubal ligation , woman hysterectomy , woman postmenopausal , woman ovary surgically remove ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>